BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 36749328)

  • 1. Management of Menopausal Symptoms: A Review.
    Crandall CJ; Mehta JM; Manson JE
    JAMA; 2023 Feb; 329(5):405-420. PubMed ID: 36749328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone Therapy and Other Treatments for Symptoms of Menopause.
    Hill DA; Crider M; Hill SR
    Am Fam Physician; 2016 Dec; 94(11):884-889. PubMed ID: 27929271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioidentical hormones for women with vasomotor symptoms.
    Gaudard AM; Silva de Souza S; Puga ME; Marjoribanks J; da Silva EM; Torloni MR
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010407. PubMed ID: 27479272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
    Parish SJ; Gillespie JA
    Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE.
    Cobin RH; Goodman NF;
    Endocr Pract; 2017 Jul; 23(7):869-880. PubMed ID: 28703650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Menopausal symptom experience before and after stopping estrogen therapy in the Women's Health Initiative randomized, placebo-controlled trial.
    Brunner RL; Aragaki A; Barnabei V; Cochrane BB; Gass M; Hendrix S; Lane D; Ockene J; Woods NF; Yasmeen S; Stefanick M
    Menopause; 2010; 17(5):946-54. PubMed ID: 20505547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study.
    Santoro N; Allshouse A; Neal-Perry G; Pal L; Lobo RA; Naftolin F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Dowling NM; Dunn M; Gleason CE; Hodis HN; Isaac B; Magnani M; Manson JE; Miller VM; Taylor HS; Wharton W; Wolff E; Zepeda V; Harman SM
    Menopause; 2017 Mar; 24(3):238-246. PubMed ID: 27779568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Women's Health Initiative Randomized Trials and Clinical Practice: A Review.
    Manson JE; Crandall CJ; Rossouw JE; Chlebowski RT; Anderson GL; Stefanick ML; Aragaki AK; Cauley JA; Wells GL; LaCroix AZ; Thomson CA; Neuhouser ML; Van Horn L; Kooperberg C; Howard BV; Tinker LF; Wactawski-Wende J; Shumaker SA; Prentice RL
    JAMA; 2024 May; 331(20):1748-1760. PubMed ID: 38691368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.
    Manson JE; Chlebowski RT; Stefanick ML; Aragaki AK; Rossouw JE; Prentice RL; Anderson G; Howard BV; Thomson CA; LaCroix AZ; Wactawski-Wende J; Jackson RD; Limacher M; Margolis KL; Wassertheil-Smoller S; Beresford SA; Cauley JA; Eaton CB; Gass M; Hsia J; Johnson KC; Kooperberg C; Kuller LH; Lewis CE; Liu S; Martin LW; Ockene JK; O'Sullivan MJ; Powell LH; Simon MS; Van Horn L; Vitolins MZ; Wallace RB
    JAMA; 2013 Oct; 310(13):1353-68. PubMed ID: 24084921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral estradiol/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens/medroxyprogesterone acetate in real-world practice.
    Panay N; Nappi RE; Stute P; Palacios S; Paszkowski T; Kagan R; Archer DF; Héroux J; Boolell M
    Maturitas; 2023 Jun; 172():23-31. PubMed ID: 37084589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging hormonal treatments for menopausal symptoms.
    Genazzani AR; Komm BS; Pickar JH
    Expert Opin Emerg Drugs; 2015 Mar; 20(1):31-46. PubMed ID: 25557757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of estrogen with and without progestin on urinary incontinence.
    Hendrix SL; Cochrane BB; Nygaard IE; Handa VL; Barnabei VM; Iglesia C; Aragaki A; Naughton MJ; Wallace RB; McNeeley SG
    JAMA; 2005 Feb; 293(8):935-48. PubMed ID: 15728164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspective on prescribing conjugated estrogens/bazedoxifene for estrogen-deficiency symptoms of menopause: a practical guide.
    Palacios S; Currie H; Mikkola TS; Dragon E
    Maturitas; 2015 Apr; 80(4):435-40. PubMed ID: 25684082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Menopausal Symptoms.
    Kaunitz AM; Manson JE
    Obstet Gynecol; 2015 Oct; 126(4):859-876. PubMed ID: 26348174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society.
    North American Menopause Society
    Menopause; 2004; 11(1):11-33. PubMed ID: 14716179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptom experience after discontinuing use of estrogen plus progestin.
    Ockene JK; Barad DH; Cochrane BB; Larson JC; Gass M; Wassertheil-Smoller S; Manson JE; Barnabei VM; Lane DS; Brzyski RG; Rosal MC; Wylie-Rosett J; Hays J
    JAMA; 2005 Jul; 294(2):183-93. PubMed ID: 16014592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial.
    Geller SE; Shulman LP; van Breemen RB; Banuvar S; Zhou Y; Epstein G; Hedayat S; Nikolic D; Krause EC; Piersen CE; Bolton JL; Pauli GF; Farnsworth NR
    Menopause; 2009; 16(6):1156-66. PubMed ID: 19609225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs for menopausal symptoms.
    Med Lett Drugs Ther; 2020 Aug; 62(1604):124-128. PubMed ID: 32960867
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study.
    Chandeying V; Sangthawan M
    J Med Assoc Thai; 2007 Sep; 90(9):1720-6. PubMed ID: 17957910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conjugated equine estrogen and medroxyprogesterone acetate are associated with decreased risk of breast cancer relative to bioidentical hormone therapy and controls.
    Zeng Z; Jiang X; Li X; Wells A; Luo Y; Neapolitan R
    PLoS One; 2018; 13(5):e0197064. PubMed ID: 29768475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.